Top

Gepubliceerd in:

Open Access 25-07-2018 | Artikel

Vroege oncologische uitkomsten van [⁶⁸Ga]PSMA-PET/CT-gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie

Auteurs: dr. Pim J. van Leeuwen, dr. Louise Emmett, drs. Maarten L. Donswijk, dr. Phillip D. Stricker, dr. Floris J. Pos, drs. Esther Wit, dr. Henk G. van der Poel

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 1/2019

Samenvatting

Deze studie toont de uitkomsten van [⁶⁸Ga]PSMA-PET/CT-gestuurde salvagetherapie bij mannen (n = 142) na radicale prostatectomie (RP) met een stijging van het prostaatspecifiek antigeen (PSA; 0,05–0,5 ng/ml). De [⁶⁸Ga]PSMA-PET/CT-scan was positief voor tumoractiviteit bij 84 mannen (36: prostaatfossa; 31: pelviene lymfeklieren ± prostaatfossa; 17: metastase op afstand). N = 88 ondergingen een salvagebehandeling (med. follow-up 12,5 mnd). Er was een PSA-respons (PSA < 0,01 of reductie >75 % in laatste PSA na salvagebehandeling) bij 69,3 % van de mannen (83 % met een negatieve PET/CT, 81 % met een positieve PET/CT in de prostaatfossa na radiotherapie op de fossa en 48,5 % bij een PET/CT die verdacht was voor een metastase in de pelviene lymfeklieren). [⁶⁸Ga]PSMA-PET/CT-imaging is instaat om patiënten met een biochemisch recidief na RP te identificeren die beter reageren op salvagetherapie.

vorige artikel Patiëntenselectie

volgende artikel Tien jaar expertise met aanpasbare continentietherapie voor post-prostatectomie urine-incontinentie

Cary KC, Punnen S, Odisho AY, et al. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis. 2015;18:149–54.CrossRef

Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–41.CrossRef

Tendulkar RD, Agrawal S, Gao T, et al. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016;34(30):9647–67. https://doi.org/10.1200/JCO.2016.67.9647 CrossRef

Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555–65.CrossRef

Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.CrossRef

Stam MA van, Aaronson NK, Pos FJ, et al. The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients. Eur Urol. 2016;70:751–7.CrossRef

Afshar-Oromieh A, Haberkorn U, Hadaschik B, et al. PET/MRI with a 68 Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1629–30.CrossRef

Leeuwen PJ van, Stricker P, Hruby G, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117:732–9.CrossRef

Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol. 2016;70:926–37.CrossRef

10.

Roach PJ, Francis R, Emmett L, et al. The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med. 2018;59:82–8.CrossRef

11.

Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–62.CrossRef

12.

Bolla M, Poppel H van, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–27.CrossRef

13.

Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66:243–50.CrossRef

14.

Valicenti RK, Thompson I Jr., Albertsen P, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013;86:822–8.CrossRef

15.

Tilki D, Preisser F, Tennstedt P, et al. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. BJU Int. 2017;119:717–23.CrossRef

16.

Morigi JJ, Stricker PD, Leeuwen PJ van, et al. Prospective comparison of 18F-fluoromethylcholine versus 68 Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90.CrossRef

17.

Budaus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69:393–6.CrossRef

18.

Leeuwen PJ van, Emmett L, Ho B, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119:209–15.CrossRef

19.

Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with (68)Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58:750–5.CrossRef

20.

Derlin T, Weiberg D, Klot C von, et al. (68)Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345–53.CrossRef

21.

Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376:417–28.CrossRef

22.

Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–8.CrossRef

23.

Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2017;44:102–7.CrossRef

Titel: Vroege oncologische uitkomsten van [68Ga]PSMA-PET/CT-gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie
Auteurs: dr. Pim J. van Leeuwen
dr. Louise Emmett
drs. Maarten L. Donswijk
dr. Phillip D. Stricker
dr. Floris J. Pos
drs. Esther Wit
dr. Henk G. van der Poel
Publicatiedatum: 25-07-2018
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Tijdschrift voor Urologie / Uitgave 1/2019
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI: https://doi.org/10.1007/s13629-018-00215-w

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen